These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3512590)

  • 1. Prolonged action of regular insulin in diabetic patients: lack of relationship to circulating insulin antibodies.
    Gardner DF; Wilson HK; Podet EJ; Arakaki RF; Nell LJ; Thomas JW; Crane MM; Field JB
    J Clin Endocrinol Metab; 1986 Apr; 62(4):621-7. PubMed ID: 3512590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Time-action characteristics of regular and NPH insulin in insulin-treated diabetics.
    Roy B; Chou MC; Field JB
    J Clin Endocrinol Metab; 1980 Mar; 50(3):475-9. PubMed ID: 6987253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The pharmacokinetics of subcutaneous regular insulin in type I diabetic patients: assessment using a glucose clamp technique.
    Gardner DF; Arakaki RF; Podet EJ; Nell LJ; Thomas JW; Field JB
    J Clin Endocrinol Metab; 1986 Sep; 63(3):689-94. PubMed ID: 3525600
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacology of a 40 IU/ml porcine lente insulin preparation in diabetic cats: findings during the first week and after 5 or 9 weeks of therapy.
    Martin GJ; Rand JS
    J Feline Med Surg; 2001 Mar; 3(1):23-30. PubMed ID: 11716627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin antibodies in diabetics receiving a single type of insulin.
    Mincu I; Cheţa D
    Med Interne; 1982; 20(1):9-13. PubMed ID: 6765628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of highly purified porcine and human insulins in diabetic patients with high titers of insulin antibody.
    Lam HC; Ho LT; Tang KT; Wang LM; Kwok CF; Liu YF; Hsiao LJ; Li SH
    Taiwan Yi Xue Hui Za Zhi; 1989 Apr; 88(4):346-51. PubMed ID: 2677227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucose-lowering effect of insulin by different routes in obese and lean nonketotic diabetic patients.
    Shahshahani MN; Kitabchi
    J Clin Endocrinol Metab; 1978 Jul; 47(1):34-40. PubMed ID: 400713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR-typed insulin-dependent diabetic individuals.
    Schernthaner G; Borkenstein M; Fink M; Mayr WR; Menzel J; Schober E
    Diabetes Care; 1983; 6 Suppl 1():43-8. PubMed ID: 6343038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of insulin antibodies.
    Kansal PC; Bandisode MS; Boshell BR
    Horm Metab Res; 1979 Mar; 11(3):187-9. PubMed ID: 447197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The immunogenic properties of highly purified insulin preparations: The clinical importance of insulin-binding antibodies.
    Anderson OO
    Acta Endocrinol (Copenh); 1975 Apr; 78(4):723-35. PubMed ID: 1173962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating antibodies in diabetics treated with conventional and purified insulins.
    Klaff LJ; Vinik AI; Berelowitz M; Jackson WP
    S Afr Med J; 1978 Jul; 54(4):149-53. PubMed ID: 694712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus.
    Burge MR; Waters DL; Holcombe JH; Schade DS
    J Clin Endocrinol Metab; 1997 Mar; 82(3):920-4. PubMed ID: 9062507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of porcine insulin and human insulin (Novo) using the glucose-controlled insulin infusion system, glucose-insulin dose-response curves, and the outpatient effectiveness of human insulin (Novo) in insulin-dependent diabetes.
    Charles MA; Szekeres A; Staten M; Worcester B; Walsh KM
    Diabetes Care; 1983; 6 Suppl 1():29-34. PubMed ID: 6343034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential response to infusions of highly purified and conventional bovine and porcine insulins.
    Nosadini R; Noy G; Kurtz AB; Alberti KG
    Diabetes; 1981 Aug; 30(8):650-5. PubMed ID: 7018969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibodies to insulin, pancreatic polypeptide, glucagon, and somatostatin in insulin-treated diabetics.
    Fitz-Patrick D; Patel YC
    J Clin Endocrinol Metab; 1981 May; 52(5):948-52. PubMed ID: 6112233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dynamics of free, total and antibody-bound insulin in diabetes mellitus patients in the process of treatment with swine insulin].
    Pliats OM; Alekseev IuP
    Probl Endokrinol (Mosk); 1977; 23(2):3-6. PubMed ID: 561956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin-mediated glucose disposal in type I diabetes: evidence for insulin resistance.
    Del Prato S; Nosadini R; Tiengo A; Tessari P; Avogaro A; Trevisan R; Valerio A; Muggeo M; Cobelli C; Toffolo G
    J Clin Endocrinol Metab; 1983 Nov; 57(5):904-10. PubMed ID: 6352727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the activity and pharmacokinetics of porcine insulin and human insulin (Novo) as assessed by the glucose clamp technique in normal and diabetic man.
    Home PD; Shepherd GA; Noy G; Massi-Benedetti M; Hanning I; Burrin JM; Alberti KG
    Diabetes Care; 1983; 6 Suppl 1():23-8. PubMed ID: 6343033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of the insulin analogue [LYS(B28),PRO(B29)] on blood glucose control.
    Trautmann ME
    Horm Metab Res; 1994 Dec; 26(12):588-90. PubMed ID: 7705764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The production and characteristics of anti-insulin, anti-A-component and anti-proinsulin antibodies in patients treated with monocomponent or conventional insulin.
    Kawazu S; Kanazawa Y; Miki E; Hayashi M; Sando H; Kajinuma H; Iwamoto Y; Akanuma Y; Kosaka K
    Acta Diabetol Lat; 1979; 16(4):339-51. PubMed ID: 399151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.